Corporate & Professional Partnerships

Here at Signature Oncology, our professional partnerships are important to us.

In 2022, Signature Oncology acquired the rights to the IFNG algorithm from The Netherlands Cancer Institute, Antoni Van Leewenhoek (NKI-AVL).

The proprietary algorithm was developed utilising the NanoString nCounter Flex Analysis System by NanoString Technologies, Inc (NASDAQ: NSTG). It is a leader in direct multiplexed digital barcode technology that enables simultaneous quantification of DNA, RNA, and proteins in any combinations.